Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Lyra Therapeutics, Inc. (LYRA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/25/2023 |
SC 13G
| Samsara BioCapital, L.P. reports a 5.6% stake in Lyra Therapeutics, Inc. |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/07/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 06/28/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 06/12/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.9% stake in Lyra Therapeutics, Inc. |
| 06/09/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 06/09/2023 |
SC 13D/A
| NBVM GP, LLC reports a 12.2% stake in LYRA THERAPEUTICS, INC. |
| 05/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Amendment No. 1 to Ninth Amended and Restated Investor Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Form of Pre-Funded Warrant, together with a schedule of Pre-Funded Warrants, each, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Form of Purchase Warrant, together with a schedule of Purchase Warrants, each, issued by Lyra Therapeutics, Inc. to the Investors set forth on such schedule",
"Securities Purchase Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Registration Rights Agreement, by and among Lyra Therapeutics, Inc. and the Investors named therein",
"Lyra Therapeutics Announces $50.0 Million Private Placement May 26, 2023 WATERTOWN, Mass., May 26, 2023 — Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis, today announced that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50.0 million, before deducting offering expenses. The closing of the private placement is subject to customary closing conditions and is expected to occur on or about May 31, 2023. Under the terms of the securities purchase agreement, Lyra has agreed to issue and sell approximately 17.7 million shares of the Company's common stock and pre-funded warrants to purc..." |
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update -- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- WATERTOWN, Mass., May 12, 2023 -- Lyra Therapeutics, Inc. , a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis , today reported its financial results for the first quarter ended March 31, 2023 and provided a corporate update. “We've had a highly productive start to 2023, positioning us for anticipated key data readouts over the next 12 months,” said Maria Palasis, Ph.D., Pre..." |
|
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/29/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G
| Nantahala Capital Management, LLC reports a 7% stake in Lyra Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| PURA VIDA INVESTMENTS, LLC reports a 6.8% stake in Lyra Therapeutics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/07/2023 |
SC 13G/A
| Polaris Venture Partners V, L.P. reports a 4.5% stake in Lyra Therapeutics, Inc. |
| 11/16/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"SIXTH AMENDMENT TO LEASE This Sixth Amendment to Lease is made as of November 14, 2022, by and between ARE-480 ARSENAL STREET, LLC, a Delaware limited liability company , and LYRA THERAPEUTICS, INC., a Delaware corporation . RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of August 14, 2007, as amended by that certain First Amendment to Lease dated as of July 21, 2008, as further amended by that certain Second Amendment to Lease dated September 4, 2012, as further amended by that certain letter agreement dated as of September 4, 2012, as further amended by that certain Third Amendment to Lease dated as of September 6, 2013, as further amended by that certain letter agreement dated January 15, 2014, as further amended by that certain Fourth Amendment to ..." |
|
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
SC 13G
| PURA VIDA INVESTMENTS, LLC reports a 8.7% stake in Lyra Therapeutics, Inc. |
| 11/02/2022 |
10-Q/A
| Quarterly Report for the period ended June 30, 2022 [amend] |
| 11/02/2022 |
10-Q/A
| Quarterly Report for the period ended March 31, 2022 [amend] |
| 10/26/2022 |
8-K
| Quarterly results |
| 09/12/2022 |
8-K
| Investor presentation |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 06/17/2022 |
8-K
| Quarterly results |
| 05/31/2022 |
8-K
| Quarterly results |
|
|
|